HERON THERAPEUTICS, INC. /DE/ — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that HERON THERAPEUTICS, INC. /DE/ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $113.56M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $105.64M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $61.94M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $52.80M | Feb 27, 2025 |
| FY2020 | Dec 31, 2020 | $11.21M | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | $12.80M | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | $13.66M | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | $14.78M | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | $19.21M | Feb 24, 2021 |
| FY2020 | Sep 30, 2019 | $25.43M | Feb 24, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($20.20M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($13.58M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($110.56M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($182.02M) | Feb 27, 2025 |
| FY2022 | Dec 31, 2021 | ($220.68M) | Mar 29, 2023 |
| FY2020 | Dec 31, 2020 | ($62.28M) | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | ($58.23M) | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | ($55.19M) | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | ($51.58M) | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | ($57.92M) | Feb 24, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.54M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($11.53M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($110.62M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($174.66M) | Feb 27, 2025 |
| FY2022 | Dec 31, 2021 | ($217.83M) | Mar 29, 2023 |
| FY2020 | Dec 31, 2020 | ($61.30M) | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | ($58.38M) | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | ($55.75M) | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | ($52.73M) | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | ($59.36M) | Feb 24, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.43M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $16.68M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $39.13M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $82.70M | Feb 27, 2025 |
| FY2022 | Dec 31, 2021 | $130.82M | Mar 29, 2023 |
| FY2020 | Dec 31, 2020 | $44.45M | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | $49.18M | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | $44.00M | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | $36.89M | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | $48.28M | Feb 24, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($27.59M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($22.53M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($58.79M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($146.91M) | Feb 27, 2025 |
| FY2022 | Dec 31, 2021 | ($203.35M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($184.82M) | Feb 28, 2022 |
| FY2021 | Dec 31, 2019 | ($124.58M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | ($191.81M) | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | ($170.30M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | ($134.10M) | Feb 22, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $317.0K | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.71M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.55M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $1.83M | Feb 27, 2025 |
| FY2022 | Dec 31, 2021 | $3.02M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $6.81M | Feb 28, 2022 |
| FY2021 | Dec 31, 2019 | $7.15M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $9.17M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $2.55M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $3.14M | Feb 22, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $255.88M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $233.15M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $222.51M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $250.95M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $305.71M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $353.56M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $512.78M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $462.18M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $234.31M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $67.48M | Feb 27, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $241.54M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $266.80M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $256.48M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $237.38M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $228.14M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $117.06M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $108.95M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $92.02M | Mar 2, 2020 |
| FY2017 | Dec 31, 2017 | $103.17M | Feb 27, 2018 |
| FY2017 | Dec 31, 2016 | $88.73M | Feb 27, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.33M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($33.65M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($33.97M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $13.57M | Feb 26, 2026 |
| FY2024 | Dec 31, 2021 | $77.57M | Feb 27, 2025 |
| FY2022 | Dec 31, 2020 | $236.49M | Mar 29, 2023 |
| FY2021 | Dec 31, 2019 | $403.84M | Feb 28, 2022 |
| FY2021 | Dec 31, 2018 | $370.16M | Feb 28, 2022 |
| FY2020 | Dec 31, 2017 | $131.14M | Feb 24, 2021 |
| FY2019 | Dec 31, 2016 | ($21.25M) | Mar 2, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.94B) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($1.92B) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($1.91B) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($1.80B) | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | ($1.61B) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($1.39B) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($1.17B) | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | ($960.72M) | Mar 2, 2020 |
| FY2018 | Jan 1, 2018 | ($781.88M) | Feb 22, 2019 |
| FY2019 | Dec 31, 2017 | ($783.46M) | Mar 2, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.65M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $25.80M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $28.68M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $15.36M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $90.54M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $105.14M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $71.90M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $31.84M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $144.58M | Feb 22, 2019 |
| FY2018 | Dec 31, 2016 | $13.41M | Feb 22, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 27, 2025 |
| FY2022 | Dec 31, 2021 | (2) | Mar 29, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 27, 2025 |
| FY2022 | Dec 31, 2021 | (2) | Mar 29, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 188.31M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 152.13M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 150.29M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 119.15M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | 102.01M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | 91.31M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 90.30M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | 78.17M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | 64.61M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | 39,355 | Feb 27, 2018 |